SNT 2.27% 4.3¢ syntara limited

What is going on?, page-63

  1. 184 Posts.
    I'd consider this a 'correction' with still a long way to go. IMO the Possible 750million coming from boehimer in the medium term, and ph11 trial payment in the short term has never been factored in to the SP . Add the inevitable upcoming announcement of Bronchidol FDA submition and its all up side with very little downside due to cash backing and reduced operation costs.

    This company made the tough decisions a couple of years ago and over the coming years will be rewarded.

    I'm interested to here others thoughts on weather new highs will ever be seen?
    I must say , minus the hype of bronchidol potential , this company has never been in a better position .
 
watchlist Created with Sketch. Add SNT (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.